These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 1361533)

  • 1. Effect of uraemia and anephric state on the pharmacokinetics of tenoxicam in the rat.
    Lopez-Bustamante LG; Troconiz JI; Fos D
    J Pharm Pharmacol; 1992 Nov; 44(11):898-901. PubMed ID: 1361533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tenoxicam pharmacokinetics in rats: a population model.
    Troconiz IF; Lopez-Bustamante LG; Fos D
    J Pharm Sci; 1995 Dec; 84(12):1482-7. PubMed ID: 8748332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tenoxicam: acute dose-dependent disposition studies in rats.
    Lopez-Bustamante LG; Troconiz JI; Fos D
    J Pharm Sci; 1993 Aug; 82(8):851-3. PubMed ID: 8377127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single- and multiple-dose pharmacokinetics, kidney tolerability and plasma protein binding of tenoxicam in renally impaired patients and healthy volunteers.
    Nilsen OG; Aasarød K; Widerøe TE; Guentert TW
    Pharmacol Toxicol; 2001 Nov; 89(5):265-72. PubMed ID: 11881981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of induced hypoalbuminemia on distribution, total clearance and unbound clearance of piroxicam in vivo in the rat.
    Troconiz JI; Lopez-Bustamante LG; Fos D
    Eur J Drug Metab Pharmacokinet; 1993; 18(2):165-71. PubMed ID: 8243500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indirect assessment of the enterohepatic recirculation of piroxicam and tenoxicam.
    Benveniste C; Striberni R; Dayer P
    Eur J Clin Pharmacol; 1990; 38(6):547-9. PubMed ID: 2373127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents.
    Olkkola KT; Brunetto AV; Mattila MJ
    Clin Pharmacokinet; 1994 Feb; 26(2):107-20. PubMed ID: 8162655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacokinetics of total and unbound concentrations of tenoxicam in synovial fluid and plasma.
    Day RO; Williams KM; Graham S; Handel M
    Arthritis Rheum; 1991 Jun; 34(6):751-60. PubMed ID: 2053921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of haemodialysis on the pharmacokinetics of tenoxicam in patients with end-stage renal disease.
    al-Ghamdi MS; al-Mohanna FA; al-Mustafa ZH; al-Saeed IS
    Eur J Clin Pharmacol; 1992; 43(2):197-9. PubMed ID: 1425878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of cholestyramine on the elimination of tenoxicam and piroxicam.
    Guentert TW; Defoin R; Mosberg H
    Eur J Clin Pharmacol; 1988; 34(3):283-9. PubMed ID: 3260866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of uremia and anephric state on the pharmacokinetics of sulindac and its metabolites in rats. I. An application of pharmacokinetic model for reversible metabolism.
    Lin JH; Yeh KC; Duggan DE
    Drug Metab Dispos; 1985; 13(5):602-7. PubMed ID: 2865111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated plasma and synovial fluid pharmacokinetics of tenoxicam in patients with rheumatoid arthritis and osteoarthritis: factors determining the synovial fluid/plasma distribution ratio.
    Hinderling PH; Hartmann D; Crevoisier C; Moser U; Heizmann P
    Ther Drug Monit; 1988; 10(3):250-60. PubMed ID: 3262939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal delivery of tenoxicam in rat.
    Raghavan CV; Abimon VD
    Int J Pharm; 2001 Jun; 221(1-2):227-9. PubMed ID: 11397584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single and multiple dose pharmacokinetics of tenoxicam in the elderly.
    Nilsen OG; Walstad RA; Eckert M; Heizmann P; Bückert A; Am T; Løge I; Unnvik J; Thue E
    Eur J Clin Pharmacol; 1988; 35(5):563-6. PubMed ID: 3266152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma tenoxicam concentrations after single and multiple oral doses.
    Crevoisier C; Heizmann P; Forgo I; Dubach UC
    Eur J Drug Metab Pharmacokinet; 1989; 14(1):23-7. PubMed ID: 2788089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview on the pharmacokinetics of tenoxicam.
    Guentert TW; Heintz RC; Joly R
    Eur J Rheumatol Inflamm; 1987; 9(2):15-25. PubMed ID: 3329107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-performance liquid chromatographic analysis of piroxicam and tenoxicam in plasma, blood and buffer solution. Application to pharmacokinetic studies in small laboratory animals.
    Troconiz JI; Lopez-Bustamante LG; Fos D
    Arzneimittelforschung; 1993 Jun; 43(6):679-81. PubMed ID: 8352822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of formulated tenoxicam transdermal delivery systems.
    Kim T; Kang E; Chun I; Gwak H
    J Pharm Pharmacol; 2008 Jan; 60(1):135-8. PubMed ID: 18088513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-steroidal anti-inflammatory drugs: restrictive or non-restrictive hepatic clearance?
    Verbeeck RK; Wallace SM
    Arzneimittelforschung; 1994 May; 44(5):683-5. PubMed ID: 8024649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood-to-brain transfer of various oxicams: effects of plasma binding on their brain delivery.
    Jolliet P; Simon N; Brée F; Urien S; Pagliara A; Carrupt PA; Testa B; Tillement JP
    Pharm Res; 1997 May; 14(5):650-6. PubMed ID: 9165538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.